In the latest trading session, 1.2 million Syros Pharmaceuticals Inc (NASDAQ:SYRS) shares changed hands as the company’s beta touched 1.33. With the company’s most recent per share price at $0.26 changed hands at -$0.01 or -3.76% at last look, the market valuation stands at $7.12M. SYRS’s current price is a discount, trading about -3042.31% off its 52-week high of $8.17. The share price had its 52-week low at $0.18, which suggests the last value was 30.77% up since then. When we look at Syros Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 42.87 million shares, with the 3-month average coming to 8.03 million.
Analysts gave the Syros Pharmaceuticals Inc (SYRS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.50. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SYRS as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Syros Pharmaceuticals Inc (NASDAQ:SYRS) trade information
Instantly SYRS was in red as seen in intraday trades today. With action -10.88%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -96.65%, with the 5-day performance at -10.88% in the red. However, in the 30-day time frame, Syros Pharmaceuticals Inc (NASDAQ:SYRS) is -89.63% down. Looking at the short shares, we see there were 4.77 million shares sold at short interest cover period of 1.38 days.
The consensus price target for the stock as assigned by Wall Street analysts is 15, meaning bulls need an upside of 98.27% from its recent market value. According to analyst projections, SYRS’s forecast low is 5 with 30 as the target high. To hit the forecast high, the stock’s price needs a -11438.46% plunge from its current level, while the stock would need to soar -1823.08% for it to hit the projected low.
Syros Pharmaceuticals Inc (SYRS) estimates and forecasts
Data shows that the Syros Pharmaceuticals Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -94.91% over the past 6 months, a 65.53% in annual growth rate that is considerably higher than the industry average of 17.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 21.16%. The 2024 estimates are for Syros Pharmaceuticals Inc earnings to increase by 73.32%.
SYRS Dividends
Syros Pharmaceuticals Inc is expected to release its next quarterly earnings report in January.
Syros Pharmaceuticals Inc (NASDAQ:SYRS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.88% of Syros Pharmaceuticals Inc shares while 75.59% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 76.26%.
